China-based Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has received the green light from the US Food and Drug Administration (FDA) to initiate a Phase II clinical study for its Category 1 chemical drug, GS1-144, in treating menopausal vasomotor symptoms (VMS).
Understanding Menopausal Vasomotor Symptoms and the Potential of GS1-144
Vasospasm symptoms (VMS), commonly referred to as hot flashes and/or night sweats, are the predominant symptoms of menopause. Currently, hormone replacement therapy (HRT) is the main treatment option available. GS1-144, a neurokinin 3 receptor (NK3R) small molecule antagonist, offers a novel approach by regulating neuronal activity in the hypothalamic thermoregulatory center. It works by blocking the binding of neurokinin B (NKB) to hypothalamic KNDy neurons, providing a non-hormonal alternative for managing menopausal VMS.
GS1-144: A Potential Game Changer in VMS Treatment
No similar product to GS1-144 has been approved in China, and the drug’s potential as a non-hormonal oral therapy for menopausal VMS is significant. It is expected to offer patients improved treatment options, potentially revolutionizing the way VMS is managed and improving the quality of life for those experiencing menopausal symptoms.-Fineline Info & Tech
